Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) Receives $27.50 Average Price Target from Analysts

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the six research firms that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $27.50.

KMTS has been the topic of a number of recent research reports. Bank of America initiated coverage on shares of Kestra Medical Technologies in a report on Monday, March 31st. They issued a "buy" rating and a $30.00 price objective on the stock. The Goldman Sachs Group lowered their price target on shares of Kestra Medical Technologies from $24.00 to $23.00 and set a "neutral" rating on the stock in a research note on Wednesday, April 16th. Piper Sandler started coverage on shares of Kestra Medical Technologies in a research note on Monday, March 31st. They set an "overweight" rating and a $27.00 price objective for the company. Wolfe Research started coverage on Kestra Medical Technologies in a research report on Monday, March 31st. They issued an "outperform" rating and a $29.00 target price on the stock. Finally, Wells Fargo & Company assumed coverage on Kestra Medical Technologies in a report on Monday, March 31st. They set an "overweight" rating and a $28.00 target price on the stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Yu Fan acquired a new stake in Kestra Medical Technologies in the 1st quarter valued at about $56,880,000. T. Rowe Price Investment Management Inc. bought a new stake in Kestra Medical Technologies in the first quarter valued at approximately $56,613,000. Omega Fund Management LLC acquired a new stake in shares of Kestra Medical Technologies in the first quarter valued at approximately $44,754,000. Alliancebernstein L.P. bought a new position in shares of Kestra Medical Technologies during the 1st quarter worth approximately $29,500,000. Finally, Brown Advisory Inc. acquired a new position in shares of Kestra Medical Technologies during the 1st quarter worth approximately $13,716,000.

Kestra Medical Technologies Trading Down 9.5%

KMTS stock traded down $1.58 during trading hours on Friday, reaching $15.07. 383,439 shares of the stock were exchanged, compared to its average volume of 124,752. The firm's 50-day simple moving average is $22.48. Kestra Medical Technologies has a 12 month low of $14.45 and a 12 month high of $26.15.

Kestra Medical Technologies (NASDAQ:KMTS - Get Free Report) last announced its earnings results on Monday, April 14th. The company reported ($1.25) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.64) by ($0.61). During the same quarter last year, the business earned ($1.18) earnings per share.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution.